New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

International Journal of Antimicrobial Agents

Volumn 55, Issue 5, 2020, Pages

  Devaux, Christian A ^a,b,c   Rolain, Jean Marc ^a,c   Colson, Philippe ^a,c   Raoult, Didier ^a,c  

^a Institut Hospitalo Universitaire   (France)

^b CNRS   (France)

^c IHU   (France)

Author keywords

Chloroquine; Coronavirus; COVID 19; SARS CoV 2

Indexed keywords

CHLOROQUINE; HYDROXYCHLOROQUINE; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE P38; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TUMOR NECROSIS FACTOR; VIRAL PROTEIN; ANTIVIRUS AGENT;

ANTIVIRAL ACTIVITY; ARTICLE; CHINA; CORONAVIRUS DISEASE 2019; DISEASE SEVERITY; DRUG REPOSITIONING; EARLY DIAGNOSIS; EMERGENCY HEALTH SERVICE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; INHIBITION KINETICS; INTERNATIONAL COOPERATION; MEDICAL RESEARCH; PATHOGENESIS; PATIENT ISOLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSMISSION; BETACORONAVIRUS; CORONAVIRUS INFECTION; DRUG EFFECT; PANDEMIC; PRECLINICAL STUDY; VIRUS PNEUMONIA;

ANTIVIRAL AGENTS; BETACORONAVIRUS; CHLOROQUINE; CORONAVIRUS INFECTIONS; DRUG EVALUATION, PRECLINICAL; HUMANS; PANDEMICS; PNEUMONIA, VIRAL;

EID: 85082451745     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2020.105938     Document Type: Article

References (101)

1. Winzeler, E.A., Malaria research in the post-genomic era. Nature 455 (2008), 751–756.
2. Parhizgar, A.R., Tahghighi, A., Introducing new antimalarial analogues of chloroquine and amodiaquine: a narrative review. Iran J Med Sci 42 (2017), 115–128.
3. editor Bruce-Chwatt, L.J., (eds.) Chemotherapy of malaria, 2nd ed., 1981, WHO, Geneva, Switzerland WHO Monograph Series 27.
4. White, N.J., Pukrittayakamee, S., Hien, T.T., Faiz, M.A., Mokuolu, O.A., Dondorp, A.M., Malaria. Lancet 383 (2014), 723–735, 10.1016/S0140-6736(13)60024-0.
5. Wellems, T.E., Plowe, C.V., Chloroquine-resistant malaria. J Infect Dis 184 (2001), 770–776.
6. Lee, S.J., Silverman, E., Bargman, J.M., The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol 7 (2011), 718–729, 10.1038/nrneph.2011.150.
7. Raoult, D., Drancourt, M., Vestris, G., Bactericidal effect of doxycycline associated with lysosomotropic agents on Coxiella burnetii in P388D1 cells. Antimicrob Agents Chemother 34 (1990), 1512–1514, 10.1128/aac.34.8.1512.
8. Raoult, D., Houpikian, P., Tissot, D.H., Riss, J.M., Arditi-Djiane, J., Brouqui, P., Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch Intern Med 159 (1999), 167–173, 10.1001/archinte.159.2.167.
9. Boulos, A., Rolain, J.M., Raoult, D., Antibiotic susceptibility of Tropheryma whipplei in MRC5 cells. Antimicrob Agents Chemother 48 (2004), 747–752.
10. Rolain, J.M., Colson, P., Raoult, D., Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infection in the 21st century. Int J Antimicrob Agents 30 (2007), 297–308.
11. Savarino, A., Boelaert, J.R., Cassone, A., Majori, G., Cauda, R., Effects of chloroquine on viral infections: an old drug against today's diseases?. Lancet Infect Dis 3 (2003), 722–727.
12. Boelaert, J.R., Piette, J., Sperber, K., The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol 20 (2001), 137–140.
13. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (2020), 497–506, 10.1016/S0140-6736(20)30183-5.
14. Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382 (2020), 727–733.
15. Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv2020 Jan 23. doi: 10.1101/2020.01.22.914952.
16. Tsiang, H., Superti, F., Ammonium chloride and chloroquine inhibit rabies virus infection in neuroblastoma cells. Arch Virol 81 (1984), 377–382.
17. Kronenberger, P., Vrijsen, R., Boeyé, A., Chloroquine induces empty capsid formation during poliovirus eclipse. J Virol 65 (1991), 7008–7011.
18. Tsai, W.P., Nara, P.L., Kung, H.F., Oroszlan, S., Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Hum Retroviruses 6 (1990), 481–489, 10.1089/aid.1990.6.481.
19. Savarino, A., Gennero, L., Sperber, K., Boelaert, J.R., The anti-HIV-1 activity of chloroquine. J Clin Virol 20 (2001), 131–135.
20. Romanelli, F., Smith, K.M., Hoven, A.D., Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity. Curr Pharm Des 10 (2004), 2643–2648.
21. Superti, F., Seganti, L., Orsi, W., Divizia, M., Gabrieli, R., Pana, A., The effect of lipophilic amines on the growth of hepatitis A virus in Frp/3 cells. Arch Virol 96 (1987), 289–296, 10.1007/bf01320970.
22. Bishop, N.E., Examination of potential inhibitors of hepatitis A virus uncoating. Intervirology 41 (1998), 261–271.
23. Mizui, T., Yamashina, S., Tanida, I., Takei, Y., Ueno, T., Sakamoto, N., et al. Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy. J Gastroenterol 45 (2010), 195–203.
24. Miller, D.K., Lenard, J., Antihistaminics, local anesthetics, and other amines as antiviral agents. Proc Natl Acad Sci U S A 78 (1981), 3605–3609, 10.1073/pnas.78.6.3605.
25. Shibata, M., Aoki, H., Tsurumi, T., Sugiura, Y., Nishiyama, Y., Suzuki, S., et al. Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine. J Gen Virol 64 (1983), 1149–1156, 10.1099/0022-1317-64-5-1149.
26. Ooi, E.E., Chew, J.S., Loh, J.P., Chua, R.C., In vitro inhibition of human influenza A virus replication by chloroquine. Virol J, 3, 2006, 39.
27. Paton, N.I., Lee, L., Xu, Y., Ooi, E.E., Cheung, Y.B., Archuleta, S., et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis 11 (2011), 677–683.
28. Yan, Y., Zou, Z., Sun, Y., Li, X., Xu, K.F., Wei, Y., et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res 23 (2013), 300–302, 10.1038/cr.2012.165.
29. De Lamballerie, X., Boisson, V., Reynier, J.C., Enault, S., Charrel, R.N., Flahault, A., et al. On Chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis 8 (2008), 837–840, 10.1089/vbz.2008.0049.
30. Khan, M., Santhosh, S.R., Tiwari, M., Lakshmana Rao, P.V., Parida, M., Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against Chikungunya virus in Vero cells. J Med Virol 82 (2010), 817–824.
31. Delogu, I., de Lamballerie, X., Chikungunya disease and chloroquine treatment. J Med Virol 83 (2011), 1058–1059.
32. Randolph, V.B., Winkler, G., Stollar, V., Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology 174 (1990), 450–458, 10.1016/0042-6822(90)90099-d.
33. Farias, K.J., Machado, P.R., de Almeida Junior, R.F., de Aquino, A.A., da Fonseca, B.A., Chloroquine interferes with dengue-2 virus replication in U937 cells. Microbiol Immunol 58 (2014), 318–326.
34. Delvecchio, R., Higa, L.M., Pezzuto, P., Valadao, A.L., Garcez, P.P., Monteiro, F.L., et al. Chloroquine, an endocytosis blocking agent, inhibits Zika virus infection in different cell models. Viruses, 8, 2016, E322, 10.3390/v8120322.
35. Glushakova, S.E., Lukashevich, I.S., Early events in arenavirus replication are sensitive to lysosomotropic compounds. Arch Virol 104 (1989), 157–161.
36. Porotto, M., Orefice, G., Yokoyama, C.C., Mungall, B.A., Realubit, R., Sganga, M.L., et al. Simulating Henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy. J Virol 83 (2009), 5148–5155.
37. Freiberg, A.N., Worthy, M.N., Lee, B., Holbrook, M.R., Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. J Gen Virol 91 (2010), 765–772, 10.1099/vir.0.017269-0.
38. Ferraris, O., Moroso, M., Pernet, O., Emonet, S., Ferrier Rembert, A., Paranhos-Baccala, G., et al. Evaluation of Crimean–Congo hemorrhagic fever virus in vitro inhibition by chloroquine and chlorpromazine, two FDA approved molecules. Antiviral Res 118 (2015), 75–81, 10.1016/j.antiviral.2015.03.005.
39. Dowall, S.D., Bosworth, A., Watson, R., Bewley, K., Taylor, I., Rayner, E., et al. Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. J Gen Virol 96 (2015), 3484–3492.
40. Kouroumalis, E.A., Koskinas, J., Treatment of chronic active hepatitis B (CAH B) with chloroquine: a preliminary report. Ann Acad Med Singapore 15 (1986), 149–152.
41. Koyama, A.H., Uchida, T., Inhibition of multiplication of herpes simplex virus type 1 by ammonium chloride and chloroquine. Virology 138 (1984), 332–335.
42. Keyaerts, E., Li, S., Vijgen, L., Rysman, E., Verbeeck, J., Van Ranst, M., et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 53 (2009), 3416–3421.
43. Blau, D., Holmes, K., Human coronavirus HCoV-229E enters susceptible cells via the endocytic pathway. editors Lavi, E., Weiss, S.R., Hingley, S.T., (eds.) The nidoviruses (coronaviruses and arteriviruses), 2001, Kluwer, New York, NY, 193–197.
44. Kono, M., Tatsumi, K., Imai, A.M., Saito, K., Kuriyama, T., Shirasawa, H., Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antiviral Res 77 (2008), 150–152, 10.1016/j.antiviral.2007.10.011.
45. Shen, L., Yang, Y., Ye, F., Liu, G., Desforges, M., Talbot, P.J., et al. Safe and sensitive antiviral screening platform based on recombinant human coronavirus OC43 expressing the luciferase reporter gene. Antimicrob Agents Chemother 60 (2016), 5492–5503, 10.1128/AAC.00814-16.
46. de Wilde, A.H., Jochmans, D., Posthuma, C.C., Zevenhoven-Dobbe, J.C., van Nieuwkoop, S., Bestebroer, T.M., et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 58 (2014), 4875–4884, 10.1128/AAC.03011-14.
47. Mo, Y., Fisher, D., A review of treatment modalities for Middle East respiratory syndrome. J Antimicrob Chemother 71 (2016), 3340–3350.
48. Burkard, C., Verheije, M.H., Wicht, O., van Kasteren, S.I., van Kuppeveld, F.J., Haagmans, B.L., et al. Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. PLoS Pathog, 10, 2014, e1004502.
49. Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30 (2020), 269–271, 10.1038/s41422-020-0282-0.
50. Gao, J., Tian, Z., Yang, X., Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends, Feb 2020, 10.5582/bst.2020.01047 [Epub ahead of print].
51. Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia [in Chinese]. Zhonghua Jie He He Hu Xi Za Zhi, 43, 2020, E019, 10.3760/cma.j.issn.1001-0939.2020.0019.
52. Bernstein, H.N., Ocular safety of hydroxychloroquine. Ann Ophthalmol 23 (1991), 292–296.
53. Ratliff, N.B., Estes, M.L., Myles, J.L., Shirey, E.K., McMahon, J.T., Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy. N Engl J Med 316 (1987), 191–193.
54. Cubero, G.J., Rodriguez Reguero, J.J., Rojo Ortega, J.M., Restrictive cardiomyopathy caused by chloroquine. Br Heart J 69 (1993), 451–452.
55. Harrison, C., Coronavirus puts drug repurposing on the fast track. Nature Biotechnology, 2020 Feb 27, 10.1038/d41587-020-00003-1.
56. Kwiek, J.J., Haystead, T.A., Rudolph, J., Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry 43 (2004), 4538–4547.
57. Varki, A., Sialic acids as ligands in recognition phenomena. FASEB J 11 (1997), 248–255.
58. Olofsson, S., Kumlin, U., Dimock, K., Arnberg, N., Avian influenza and sialic acid receptors: more than meets the eye?. Lancet Infect Dis 5 (2005), 184–188.
59. Vincent, M.J., Bergeron, E., Benjannet, S., Erickson, B.R., Rollin, P.E., Ksiazek, T.G., et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J, 2, 2005, 69, 10.1186/1743-422X-2-69.
60. Tricou, V., Minh, N.N., Van, T.P., Lee, S.J., Farrar, J., Wills, B., et al. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis, 4, 2010, e785, 10.1371/journal.pntd.0000785.
61. Gay, B., Bernard, E., Solignat, M., Chazal, N., Devaux, C., Briant, L., pH-dependent entry of Chikungunya virus into Aedes albopictus cells. Infect Genet Evol 12 (2012), 1275–1281, 10.1016/j.meegid.2012.02.003.
62. Yang, Z.Y., Huang, Y., Ganesh, L., Leung, K., Kong, W.P., Schwartz, O., et al. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol 78 (2004), 5642–5650, 10.1128/JVI.78.11.5642-5650.2004.
63. Wang, H., Yang, P., Liu, K., Guo, F., Zhang, Y., Zhang, G., et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res 18 (2008), 290–301, 10.1038/cr.2008.15.
64. Cassell, S., Edwards, J., Brown, D.T., Effects of lysosomotropic weak bases on infection of BHK-21 cells by Sindbis virus. J Virol 52 (1984), 857–864.
65. Savarino, A., Lucia, M.B., Rastrelli, E., Rutella, S., Golotta, C., Morra, E., et al. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndr 35 (1996), 223–232.
66. Harley, C.A., Dasgupta, A., Wilson, D.W., Characterization of herpes simplex virus-containing organelles by subcellular fractionation: role for organelle acidification in assembly of infectious particles. J Virol 75 (2001), 1236–1251.
67. Klumperman, J., Locker, J.K., Meijer, A., Horzinek, M.C., Geuze, H.J., Rottier, P.J., Coronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding. J Virol 68 (1994), 6523–6534.
68. Perrier, A., Bonnin, A., Desmarets, L., Danneels, A., Goffard, A., Rouillé, Y., et al. The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal. J Biol Chem 294 (2019), 14406–14421.
69. Diebold, S.S., Kaisho, T., Hemmi, H., Akira, S., Reis e Sousa, C., Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303 (2004), 1529–1531.
70. + T cell responses against soluble antigens in vivo. J Exp Med 202 (2005), 817–828.
71. Garulli, B., Di Mario, G., Sciaraffia, E., Accapezzato, D., Barnaba, V., Castrucci, M.R., Enhancement of T cell-mediated immune responses to whole inactivated influenza virus by chloroquine treatment in vivo. Vaccine 31 (2013), 1717–1724, 10.1016/j.vaccine.2013.01.037.
72. Steiz, M., Valbracht, J., Quach, J., Lotz, M., Gold sodium thiomalate and chloroquine inhibit cytokine production in monocytic THP-1 cells through distinct transcriptional and posttranslational mechanisms. J Clin Immunol 23 (2003), 477–484, 10.1023/B:JOCI.0000010424.41475.17.
73. lck is required for triggering NF-κB activation upon interaction of human immunodeficiency virus type 1 envelope glycoprotein gp120 with cell surface CD4. J Virol 72 (1998), 6207–6214.
74. Fuld, H., Horwich, L., Treatment of rheumatoid arthritis with chloroquine. Br Med J 15 (1958), 1199–1201, 10.1136/bmj.2.5106.1199.
75. Mackenzie, A.H., Antimalarial drugs for rheumatoid arthritis. Am J Med 75 (1983), 48–58.
76. Sharma, T.S., Do, E.J., Wasko, M.C.M., Anti-malarials: are there benefits beyond mild disease?. Curr Treat Options Rheumatol 2 (2016), 1–12, 10.1007/s40674-016-0036-9.
77. Wozniacka, A., Lesiak, A., Narbutt, J., McCauliffe, D.P., Sysa-Jedrzejowska, A., Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus 15 (2006), 268–275.
78. Sharma, O.P., Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. Arch Neurol 55 (1998), 1248–1254.
79. Jang, C.H., Choi, J.H., Byun, M.S., Jue, D.M., Chloroquine inhibits production of TNF-α, IL-1β and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology 45 (2006), 703–710.
80. Picot, S., Peyron, F., Donadille, A., Vuillez, J.-P., Barbe, G., Ambroise-Thomas, P., Chloroquine-induced inhibition of the production of TNF, but not of IL-6, is affected by disruption of iron metabolism. Immunology 80 (1993), 127–133.
81. Jeong, J.Y., Jue, D.M., Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages. J Immunol 158 (1997), 4901–4907.
82. Zhu, X., Ertel, W., Ayala, A., Morrison, M.H., Perrin, M.M., Chaudry, I.H., Chloroquine inhibits macrophage tumour necrosis factor-α mRNA transcription. Immunology 80 (1993), 122–126.
83. Weber, S.M., Levitz, S.M., Chloroquine interferes with lipopolysaccharide-induced TNF-α gene expression by a nonlysosomotropic mechanism. J Immunol 165 (2000), 1534–1540, 10.4049/jimmunol.165.3.1534.
84. Jeong, J.Y., Choi, J.W., Jeon, K.I., Jue, D.M., Chloroquine decreases cell-surface expression of tumour necrosis factor receptors in human histiocytic U-937 cells. Immunology 105 (2002), 83–91, 10.1046/j.0019-2805.2001.01339.x.
85. Wang P.H., Cheng Y.Increasing host cellular receptor—angiotensin-converting enzyme 2 (ACE2) expression by coronavirus may facilitate 2019-nCoV infection. bioRxiv2020 Feb 27. doi: 10.1101/2020.02.24.963348.
86. Li, R., Qiao, S., Zhang, G., Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV. J Infect, 2020 Feb 21, 10.1016/j.jinf.2020.02.013 [Epub ahead of print].
87. Zeng, Q., Langereis, M.A., van Vliet, A.L.W., Huizinga, E.G., de Groot, R.J., Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution. Proc Natl Acad Sci U S A 105 (2008), 9065–9069.
88. Bakkers, M.J.G., Lang, Y., Feistsma, L.J., Hulswit, R.J.G., de Poot, S.A.H., van Vliet, A.L.W., et al. Betacoronavirus adaptation to humans involved progressive loss of hemagglutinin-esterase lectin activity. Cell Host Microbe 21 (2017), 356–366, 10.1016/j.chom.2017.02.008.
89. Simmons, G., Bertram, S., Glowacka, I., Steffen, I., Chaipan, C., Agudelo, J., et al. Different host cell proteases activate the SARS-coronavirus spike-protein for cell–cell and virus–cell fusion. Virology 413 (2011), 265–274, 10.1016/j.virol.2011.02.020.
90. Colson, P., Rolain, J.M., Lagier, J.C., Brouqui, P., Raoult, D., Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents, 2020 Mar 4, 105932, 10.1016/j.ijantimicag.2020.105932.
91. Graham, R.L., Donaldson, E.F., Baric, R.S., A decade after SARS: strategies to control emerging coronaviruses. Nat Rev Microbiol 11 (2013), 836–848.
92. Milewska, A., Zarebski, M., Nowak, P., Stozek, K., Potempa, J., Pyrc, K., Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells. J Virol 88 (2014), 13221–13230.
93. Collins, A.R., HLA class I antigen serves as a receptor for human coronavirus OC43. Immunol Invest 22 (1993), 95–103.
94. Zhao, X., Guo, F., Liu, F., Cuconati, A., Chang, J., Block, T.M., et al. Interferon induction of IFITM proteins promotes infection by human coronavirus OC43. Proc Natl Acad Sci U S A 111 (2014), 6756–6761.
95. Vlasak, R., Luytjes, W., Spaan, W., Palese, P., Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses. Proc Natl Acad Sci U S A 85 (1988), 4526–4529.
96. Huang, X., Dong, W., Milewska, A., Golda, A., Qi, Y., Zhu, Q.K., et al. Human coronavirus HKU1 spike protein uses O-acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme. J Virol 89 (2015), 7202–7213.
97. Chan, C.M., Lau, S.K.P., Woo, P.C.Y., Tse, H., Zheng, B.J., Chen, L., et al. Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. J Virol 83 (2009), 1026–1035.
98. Millet, J.K., Whittaker, G.R., Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc Natl Acad Sci U S A 111 (2014), 15214–15219.
99. Zhao Y., Zhao Z., Wang Y., Zhou Y., Ma Y., Zuo W.Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv2020 Jan 26. doi: 10.1101/2020.01.26.919985.
100. Glowacka, I., Bertram, S., Müller, M.A., Allen, P., Soilleux, E., Pfefferle, S., et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol 85 (2011), 4122–4134.
101. Fehr, A.R., Perlman, S., Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 1282 (2015), 1–23, 10.1007/978-1-4939-2438-7_1.